Article Sidebar
Published:
Oct 8, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Therapeutic effect of Sijunzi decoction on ulcerative colitis: A study based on in vitro functional experiments
Abstract
Purpose: To investigate the efficacy of Sijunzi decoction (SJZD) against ulcerative colitis (UC) in vitro, and to unravel the probable mechanism of action.
Methods: SEC-6 cells were exposed to lipopolysaccharide (LPS) in order to establish an ulcerative colitis model, and then treated with SJZD. CCK-8 assay was employed to evaluate cell viability, while cell apoptosis was determined by flow cytometry. Enzyme-linked immunosorbent assay (ELISA) and quantitative real-time polymerase chain reaction (qRT-PCR) were used to assess inflammation factors, viz, TNF-α, IL-1β and IL-6, whereas the expression levels of Bax, Bcl-2 and peroxisome proliferatoractivated receptors (PPARs) were evaluated by Western blot.
Results: SJZD doses of 80 and 160 mg/L increased cell viability in LPS-induced SEC-6 cells, while Bcl2 and Bax expressions were regulated, and apoptosis inhibited at these doses (p < 0.05), indicating that SJZD attenuated cell apoptosis. Inflammation was also repressed by SJZD, based on the reduced expressions of TNF-α, IL-1β and IL-6 (p < 0.05). Furthermore, SJZD significantly increased PPARα level, thus enhancing cell viability, inhibiting apoptosis as well as inhibiting inflammation (p < 0.05).
Conclusion: SJZD lowers cell damage, and inhibits cell apoptosis and inflammation through the activation of PPARα pathway, thus suggesting that SJZD is a potential therapeutic candidate for the treatment of ulcerative colitis.
